Displaying drugs 14851 - 14875 of 15108 in total
GDC-0349
GDC-0349 has been used in trials studying the treatment of Non-Hodgkin's Lymphoma, Solid Tumor.
Investigational
4-(2-amino-1,3-thiazol-4-yl)phenol
Experimental
1-(2-HYDROXYETHYLOXYMETHYL)-6-PHENYL THIOTHYMINE
Experimental
ND1251
ND1251 is an orally active phosphodiesterase-4 (PDE4) inhibitor, a mechanism clinically proven to play a role in alleviating symptoms of depression. ND1251 is a very potent compound with a large safety margin. ND1251 may also have applications in other disorders, such as Alzheimer's disease, mild cognitive impairment, multiple sclerosis and...
Investigational
Matched Description: … applications in other disorders, such as Alzheimer's disease, mild cognitive impairment, multiple sclerosis and …
R411
R411 is a non-steroid oral medicine for the treatment of asthma. It is not immunosuppressive, but blocks the activation and recruitment of cells involved in respiratory inflammation. It is a dual-acting competitive integrin antagonist (as compared to previously developed single integrin antagonists or SIAs) that prevents binding of V-CAM1 to...
Investigational
Matched Description: … It is not immunosuppressive, but blocks the activation and recruitment of cells involved in respiratory …
PKI-179
PKI-179 has been used in trials studying the treatment of Advanced Malignant Solid Tumors.
Investigational
Cenerimod
Cenerimod has been used in trials studying the treatment of Systemic Lupus Erythematosus.
Investigational
Rimiterol
Experimental
Trelagliptin
Trelagliptin is under investigation in clinical trial NCT03555591 (Specified Drug-Use Survey of Trelagliptin Tablets "Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus").
Investigational
Verucerfont
Verucerfont has been used in trials studying the treatment of Congenital Adrenal Hyperplasia.
Investigational
ATX-201
ATX-201 is one of a family of novel compounds that inhibits microtubule polymerization. It is developed by Kythera Biopharmaceuticals, Inc. for the treatment of actinic
keratosis. The company announced the decision to discontinue its ATX-201 clinical program for actinic keratosis. The Company determined that the program was not meeting their...
Investigational
Matched Description: … The Company determined that the program was not meeting their expected primary and exploratory objectives …
(1S,2R,3S,4R,5R)-2,3,4-trihydroxy-N-octyl-6-oxa-8-azabicyclo[3.2.1]octane-8-carbothioamide
(1S,2R,3S,4R,5R)-2,3,4-trihydroxy-N-octyl-6-oxa-8-azabicyclo[3.2.1]octane-8-carbothioamide is a solid. This compound belongs to the oxepanes. These are compounds containing an oxepane ring, which is an a seven-member saturated aliphatic heterocycle with one oxygen and six carbon atoms. This drug targets the protein beta-glucosidase A.
Experimental
Matched Description: … containing an oxepane ring, which is an a seven-member saturated aliphatic heterocycle with one oxygen and …
8-chlorotheophylline
8-Chlorotheophylline is a stimulant drug of the xanthine chemical class, with physiological effects similar to caffeine. Its main use is in combination with Diphenhydramine as the antiemetic drug Dimenhydrinate. The stimulant properties of 8-chlorotheophylline are thought to ward off the drowsiness caused by diphenhydramine's anti-histamine activity in the central nervous...
Experimental
Matched Description: … chlorotheophylline produces a number of effects including nervousness, restlessness, insomnia, headache, and …
CHS-828
CHS-828 has been used in trials studying the treatment of Unspecified Adult Solid Tumor, Protocol Specific.
Investigational
Displaying drugs 14851 - 14875 of 15108 in total